Opinion|Videos|July 8, 2024
Increasing Awareness of RSV Vaccines in At-Risk Patients
The expert panel discusses ways to increase awareness of the RSV vaccine for patients who would benefit from it.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- With adult RSV vaccines recently approved, how can healthcare providers increase awareness for at-risk populations and educate on infection prevention strategies?
- How has limited public awareness of adults at risk for RSV infections impacted clinical practice?
- How has limited public awareness of adults at risk for RSV infections impacted clinical practice?
Advertisement
Related to this article
In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Advertisement
Advertisement
Trending on AJMC
1
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
5